Ind-Swift Laboratories Ltd. Regd. Off.: SCO 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101 CIN No.124232CH1995PLC015553

	Quarter Ended			Half Year Ended		Year Ende
PARTICULARS	30/09/2015		30/09/2014		30/09/2014	
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
income from Operations			- 11			
(a) Net Sales incomes from Operations	16092.27	16968.93	15996.19	33061.20	34407.06	64573.6
(b) Other Operating Income	282.19	363.99	203.25	646.18	653.66	
Total Net Sales / Operating Income	16374.47	17332.91	16199.44	33707.38	35060.72	66799.0
Total Expenditure : a Cost of Malena's Consumed	9049.11	0400.00	2000 00			
b Purchase of stock in Trade	200 4111	9106.53	9233 90	18155.64	18251.68	33869.6
or Increase) /decrease in FG. WIP & stock in trade	55.22 181.71	116.09 804.15	1234.65 (550.75)	171.31 985.87	4320.06	4568.8
d Staff cost	1596.96	1404.59	1313.77	3001.55	(169.08) 2494.85	1409.1 5228.6
e Depreciation	2141.43	2090.85	1652 79	4232.28	3465.31	8429.0
f. Other expenditure	2346.15	2823.72	2101.29	5169.86	4378.43	10584.6
TOTAL	15370.57	16345.93	14985.66	31716.50	32741.25	
Profit/(Loss) from Operations before Other Income.	1003.89	986.98	1213.79	1990.88	2319.48	2709.2
Interest & Exceptional Items						
Misc Income	0.00	0.00	0.00	0.00	0.00	0.0
Profit/(Loss) before Interest & Exceptional Items	1003.89	986.98	1213.79	1990.88	2319.48	2709.2
olerest	2573.68	2619,19	3126.26	5192.87	5943,28	11918.7
Profit/(Loss) after Interest but before Exceptional Items	(1569.79)	(1632.20)	(1912.48)	(3201.99)	(3623.80)	(9209.5
Exceptional items	0.00	0.00	0.00	0.00	0.00	5118.9
Profit(+)/ Loss(-) from Ordinary Activities before tax Provision for taxation	(1569.79)	(1632.20)	(1912.48)	(3201.99)	(3623.80)	
Income Tax adjustment of Previous Year	0.00	0.00	0.00	0.00	0.00	0.0
Mat Credit Entitlement	0.00	0.19	(35.96)	0.00	(35.77)	(34.8)
Provision for deferred Tax	0.00	0.00	0.00	0.00	0.00	0.0
Net Profit/(Loss) from ordinary activities after Tax	(1569.79)	(1632.20)	(1876.52)	(3201.99)	(3588.03)	(11916.3
	and the same of th		The state of the s	and communicated	endancero manada	
Paid up Equity Share Capital (Face Value of Rs. 10/- per Share)	4096.32	4096.32	4096.32	4096.32	4096.32	4096.3
R-serves excluding revaluation reserves EPS (Rs.)	-		-	-	-	1108
Basic	(3.83)	(3.96)	(4.18)	(7.82)	(8.76)	(29.0)
Deuted	(3.83)	(3.98)	(4.18)	(7.82)	(8.76)	(29.00
PARTICULARS OF SHAREHOLDING		17 28				
Public Shareholding						
Numbers of shares	19406344	19406344	19406344	19406344	19406344	1940634
% of Shareholding	47.38	47.38	47.38	47.38	47.38	47.3
Promoters and Promoter group shareholding						
Pledged/Encumbered			1	10.00		
-Number of Shares	21556851	21556851	19864126	21556851	19864126	2155685
Percentage of shares (as a % of total shareholding	100	100	92.15	100	92.15	10
of promoter & promoters group)		To land				200
Percentage of shares (as a % of total share capital	52.62	52.62	48.49	52.62	48.49	52.6
of the Company)				W.		7.50
Non-ensumbered						
- Number of Shares	Nil	Nil	1692725	Nil	1692725	
 Percentage of shares (as a % of total shareholding of promoter & promoters group) 	Nil	Nil	7 85	Nii	7.85	N
Percentage of shares (as % of total share capital	Nel	Nil	4.13	N/a	4 13	
of the Company)	180	Dest	4,13	Nel	4,13	N
NVESTOR COMPLAINTS - QUARTER ENDED 30.09.20						
Pending at the beginning of the Quarter	NIL		ff during the			NIL
Received during the Quarter	NIL	Remaining	unresolved a	d the end of		NIL
STANDALONE STATEMENT OF ASSETS & LIABILITIES	3			ANY LOSS AND ADDRESS	- ((in Lacs)
Particulars				Un-audit As At Half Year 30/09/201	Ended As A	Year End
EQUITY AND LIABILITIES				30/09/201	3 3	1/03/2015
1) Shareholders' Funds						
			HE STATE	100	00 22	4.000.0
a) Share Capital b) Reserves & Surplus				4,096.32 51,936.89 1,807.73		4,096.3
						55,139.14 1156.00
2) Share Application money pending Allotment				1,00	11.13	1100.00
3) Non-current liabilities						
Share Application money pending Allotment Non-current liabilities (a) Long-term borrowings				100,60		98,920.3

Particulars	As At Half Year Ended 30/09/2015	As At Year Ended 31/03/2015
I EQUITY AND LIABILITIES		
(1) Shareholders' Funds		
a) Share Capital	4.096.32	4,096,32
b) Reserves & Surplus	51,936,89	55,139,14
(2) Share Application money pending Allotment	1,807.73	1156.00
(3) Non-current liabilities		
(a) Long-term borrowings	100,606.99	98,920.37
(4) Current Liabilities		
Fail Short term Borrowings	44,206,20	43,292.18
(h)Trade Payables	15,645.02	14,686.36
ic) Other current liabilities	6,339.39	6,536.82
TOTAL	224.638.54	223,827,19
II. ASSETS		
(1) Non-Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	117,108.10	117,111.16
(ii) Inlangible Assets	21,505.94	23,086.81
(iii) Capital work in Progress (Tangible)	11,536.04	9,340.52
fiviCapitat work in Progress (Intangible)	2,574.40	1,942.98
(v) Assets held for disposal	222.26	222.25
	152,946.73	151,683.73
Accumulated depreciation	31,390.73	28,739.87
Net Block	121,556.00	122,943.86
(b) Nnn-Current investment	2,638.16	2833.16
(c) Deffered Tax Liabilities(Net)	4,81.06	4,81.06
(d) Long-term loans & advances	79,00.93	7197.17
(2) Current Assets		
(a) Inventories	34,395.94	34830.69
(b) Trade receivables	38,971.41	37490.01
(c) Cash and cash equivalents	24.55.88	1,847.73
(d) Short-term loans and advances	16,239.16	16,403.52
TOTAL	224,638.54	223,827.19

Notes:-

- To During the quarter the Company has received Rs. 6,51,72,860 towards promoters contribution from promoters as per the terms of CDR. The funds have been utilized for Long term working capital requirement.

 2. During the quarter company has created a provision for doubtful debts of Rs. 4,63 Crores proportionately on estimated.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings neid on 24th October, 2015.

 4. The previous peniod figures have been re-grouped and re-arranged wherever necessary.

 5. The Company is exclusively in the Pharmaceutical Business segment.

For Ind-swift Laboratories Limited

Sd/[N.R. Munjal]
Vice-Chairman-cum-Managing Director

For Ind-Swift Laboratories Ltd pand dark

GM-Corporate Affairs & Company Secretary

S.C.O. 819-20, Sector-22 A, Chandigarh 160 022 Phone: 0172-2705761, 2701629 Fax: 0172-5089769 Email: jainassociates1968@rediffmail.com

JA/SCP/2015-16/47

LIMITED REVIEW

The Board of Directors Ind-Swift Laboratories Ltd. S.C.O. 850, NAC Manimajra Chandigarh

We have reviewed the accompanying statement of unaudited financial results of Ind-Swift Laboratories Ltd for the Quarter ended 30.09.2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a reports on these financial statements based on our review.

We conducted our review in accordance with the standard on review Engagement (SRE) 2400, engagements to review Financial Statements issued by the Institute of chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurances than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies has not disclosed the information that are required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that is contains any material misstatement.

FOR JAIN & ASSOCIATES Chartered Accountants (Regd No.:001361N)

Membership No 10194

Place: Chandigarh Date: 24.10.2015

(Pardeep Verma)
GM-Corporate Affairs & Company Secretary

For Ind-Swift Laboratories